ICYMI, this week we had stories about the role of precision medicine for managing melanoma, a debridement drug for severe pediatric burns, roflumilast cream phase 3 results, and an exclusive KOL interview.
Click here to answer this week's poll.
Continued research and development are resulting in exciting new treatment options for major dermatological conditions.
This week's edition of the Mainstream Patient features stories about skin cycling, skin care routines from dermatologists, upcoming nail trends, body care, and more.
Patients prefer virtual appointments for common ailments, but question the quality of care.
Precision medicine may help improve the diagnosis and management of melanoma.
MediWound’s debridement drug will provide a safer non-surgical alternative to severe thermal burns for pediatric patients.
Arcutis Biotherapeutics’ roflumilast cream showed higher efficacy compared to vehicle in two phase 3 studies.
Mark G. Lebwohl, MD, and Joseph F. Merola, MD, MMSc, discuss updates in the pathogenesis of PsA and PsO.
A national study in Germany identified the baseline characteristics of patients with moderate-to-severe atopic dermatitis (AD) to understand how they are usually treated with Dupixent in the real world.
Drs Mark G. Lebwohl and Joseph F. Merola discuss how patient presentation differs in patients with PsO and PsA.
The CHMP's recommendations are based on data from a phase 3 ECZTRA 6 trial in adolescents with moderate-to-severe AD cases.
Zoe Diana Draelos, MD, answers questions about the function of peptides in skin care.
In this week’s Pointers with Dr Portela, the 208SkinDoc reviews a video of laser tattoo removal.
The occurrence of immune-mediated inflammatory diseases (IMID) is higher in patients with inflammatory bowel disease (IBD) than in the general population.
Federal AHRQ offers starting point for reducing greenhouse gas emissions.
Roflumilast cream adds a much-needed element of simplicity for psoriasis patients and their dermatologists.